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Inconsistency amongst the diagnostic  
criteria based on Ewing’s tests for  
diagnosing cardiac autonomic neuropathy 
in diabetes mellitus: an under-rated issue
Cardiac autonomic neuropathy (CAN) is a com-
mon yet overlooked complication of diabetes mellitus 
(DM) [1]. CAN poorly correlates with specific symptoms 
or clinical signs implying that it frequently remains 
unrecognized until late in the disease trajectory [2]. 
Moreover, the reported prevalence of CAN varies 
greatly from as low as 17% to as high as 73% [3, 4]. 
This huge variation in the prevalence of CAN is in part 
due to different diagnostic criteria used to identify 
CAN in various trials. Cardiovascular autonomic reflex 
tests (CARTs) [consists of 5 heart rate (HR) and blood 
pressure (BP) tests] proposed by Ewing et al. [5] are 
considered as the gold standard tests for diagnosing 
CAN in DM. There are various criteria which utilizes 
Ewing’s test for diagnosing and staging CAN. Most 
widely used among these criteria is the Ewing’s criterion 
which classifies CAN into no-CAN (all tests normal or 
1 test borderline), early (1 HR test abnormal or 2 bor-
derline), definite (two HR test abnormal) and severe 
(2 HR test abnormal + 1 or both BP tests abnormal) 
CAN category [5]. This criterion is based on the theoreti-
cal conception that sympathetic dysfunction precedes 
parasympathetic dysfunction in diabetic CAN and 
hence classifies patients with borderline HR test (which 
examines parasympathetic dysfunction) as early or 
definite CAN and those with borderline or abnormal BP 
test (which examines sympathetic dysfunction) along 
with abnormal HR tests under severe category. In DM, 
similar to peripheral neuropathy, the autonomic neural 
dysfunction progresses in a length dependent fashion 
and the vagus nerve (longest autonomic nerve which 
mediates 75% of all parasympathetic activity) fibers 
are affected first followed by sympathetic denervation 
in the later stages [6]. The above discussion makes it 
clear that Ewing’s criterion was certainly influenced 
by the sequential trend of autonomic dysfunction in 
diabetic CAN. On the contrary, some investigations 
have found a simultaneous occurrence of sympathetic 
and parasympathetic dysfunction without any chrono-
logical order for the development of CAN and on rare 
occasions abnormalities in BP tests may precede the 
abnormalities in HR tests in DM patients which makes 
the sequential staging of CAN by Ewing’s criterion 
questionable [7–9]. There are various other classifica-
tion criteria (based on Ewing’s test) which are being 
used by researchers. Bellavere’s criteria include only 
HR tests [deep breathing test (DBT), Valsalva maneuver 
(VM), and 30:15 ratio] into consideration and thus 
does not examine CAN holistically leaving the as-
sessment of cardiac sympathetic function untouched 
[10]. Furthermore, CAN subcommittee of the Toronto 
Consensus Panel on diabetic neuropathy suggested 
combined examination of both CARTs and frequency 
domain indices of heart rate variability (low frequency 
power, high frequency power and LF/HF ratio) as 
a robust measure of CAN diagnosis. It staged CAN into 
early (1 positive test), definitive (2 or 3 positive test) and 
severe (orthostatic hypertension + one of the previous 
criterion) stages without contemplating the trend of 
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cardiac autonomic dysfunction in DM [11]. Mendivill et 
al. [12] examined the presence of CAN solely by HR tests 
(DBT, VM, 30:15 ratio) which led to higher reported 
prevalence (68%) of the disease in that study. Kempler 
et al. [13] considered only two tests (30:15 ratio and 
postural drop in BP) rather than the whole battery of 
CART for diagnosing CAN in DM patients and reported 
a much lower prevalence of the disease (36%). Similarly, 
many such studies exists which have not considered 
the entire Ewing’s test battery and have either as-
sessed sympathetic or vagal dysfunction and have left 
undiagnosed cases (6, 15, 16). For that reason, there is 
huge discrepancy in the combination of CARTs and the 
criteria used for the diagnosis and staging of CAN which 
has definitely contributed to incongruity in the reported 
prevalence of this condition across the population. This 
inconsistency is an important gap in the literature which 
needs to be addressed because using a particular group 
of CARTs might lead to either many under-diagnosed or 
incorrectly categorized cases. A more holistic and universal 
criterion should be designed by future studies for early 
and definitive diagnosis of CAN which considers early to 
advance dysfunction of autonomic nervous system rather 
than parasympathetic to sympathetic since there is still 
no clear consensus on the trend of autonomic dysfunc-
tion in DM. If the future researches could develop a more 
accurate criteria and implement a more consistent use 
of the same across the studies working towards diabetic 
CAN, an accurate diagnosis and staging of CAN would 
be possible which may help clinicians in implementing 
timely and appropriate management strategies. Also, an 
universal diagnostic and staging criterion will sought out 
the variability in the reported prevalence of the disease 
and will make the comparison across different studies 
easier for research professionals working in the area of 
cardiovascular diabetology. 
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